Homocysteine and atherothrombosis

E Falk1, J Zhou, J Møller

  • 1Department of Cardiology, Aarhus University Hospital (Skejby), Denmark. Erling.Falk@iekf.au.dk

Lipids
|February 12, 2002
PubMed

Insights

Current evidence does not establish homocysteine as a cause of atherothrombotic diseases like ischemic heart disease. Elevated homocysteine may be a marker, not a cause, of these conditions.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disease Research
  • Nutritional Epidemiology

Background:

  • Atherosclerosis underlies major cardiovascular diseases, including ischemic heart disease (IHD) and stroke.
  • The link between homocysteine and atherothrombotic diseases is debated, with conflicting evidence from various study types.
  • Severe hyperhomocysteinemia causes cardiovascular issues, but IHD is rare in these patients, unlike in the general population.

Purpose of the Study:

  • To critically evaluate the causal role of homocysteine in the pathogenesis of atherothrombotic diseases.
  • To assess whether observed associations between plasma homocysteine and IHD meet criteria for causality.
  • To explore alternative explanations for the homocysteine-atherothrombosis relationship.

Main Methods:

  • Review of genetic, observational, and experimental studies on homocysteine and atherothrombosis.
  • Analysis of criteria for inferring causality from observational data (temporality, consistency, strength, etc.).
  • Examination of experimental data in animal models, including comparisons between normal and hypercholesterolemic subjects.

Main Results:

  • Evidence for a causal role of homocysteine in atherothrombosis is not clearly established, even in genetically hyperhomocysteinemic individuals.
  • Epidemiological associations between plasma homocysteine and IHD do not consistently meet causality criteria.
  • Plasma homocysteine levels are influenced by diet and may reflect atherothrombosis or associated behaviors rather than causing it.
  • Experimental studies show hyperhomocysteinemia is not inherently atherogenic in normal animals.

Conclusions:

  • The homocysteine hypothesis of atherosclerosis lacks definitive proof.
  • Plasma homocysteine is unlikely to be a direct cause of atherothrombotic disease in the general population.
  • Further research in atherogenic animal models is needed to clarify homocysteine's role under specific conditions.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...